Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture

2026-02-28 09:47:19 ET

Thesis

Emergent BioSolutions Inc. ( EBS ) closed about 27% lower on Friday. I think it’s safe to say that the slide was driven less by the 2025 results but more by a major negative reset in 2026 expectations . Management guided to just $720 to $760 million in 2026 revenue, a range that was far below the roughly $1.0 billion level that analysts had been modelling. Elsewhere, management guided for adjusted EBITDA of $135 to $155 million, down from $205 million in 2025, alongside an expected return to a GAAP net loss. So overall, it didn’t make for great viewing, and the size of the expectations gap, not just the weaker fundamentals, which I’ll get to, is what really hurt the stock price. Now, I think the sheer size of the guidance told us that 2025 profitability was boosted by a pretty favourable mix and cost dynamics that will not repeat any time soon. The competitive pressure on naloxone, combined with the uneven government procurement, should weigh rather heavily on 2026. So overall, with lower revenue on the horizon and a sharp dip in profitability expected, I wouldn't be too bullish on Emergent shares, which now find themselves trading in the $8 range....

Read the full article on Seeking Alpha

For further details see: